疑似心绞痛患者接受CT冠状动脉造影后的症状与生活质量:一项随机对照试验
在4146例疑似心绞痛患者中,与单纯标准治疗相比,标准治疗加CT冠状动脉造影(CTCA)在6个月时身体受限、心绞痛频率和生活质量的改善幅度更小;接受CTCA者中,诊断为正常冠状动脉或停用预防治疗者症状改善最大,而中度非阻塞性病变或新处方预防治疗者改善最小。
要点
- CTCA组6个月时身体受限、心绞痛频率和生活质量改善均小于单纯标准治疗组。
- 接受CTCA者中,正常冠状动脉或停用预防治疗者症状改善最大,中度非阻塞性病变或新处方预防治疗者改善最小。
- CTCA在改善诊断、治疗和结局的同时,因检出中度非阻塞性冠状动脉疾病而使症状和生活质量改善轻度减弱。
核心结论
- CTCA在改善诊断、治疗和结局的同时,因检出中度非阻塞性冠状动脉疾病而与症状和生活质量改善的小幅减弱相关。
研究设计与样本
- 前瞻性开放标签平行组多中心随机对照试验,4146例疑似冠心病所致心绞痛患者按1:1随机接受标准治疗或标准治疗加CTCA。
- 使用西雅图心绞痛问卷和简表12在6个月内评估症状和生活质量。
主要发现
- 基线评分显示轻度身体受限(74±0.4)、中度心绞痛稳定性(44±0.4)、轻度心绞痛频率(68±0.4)、极好治疗满意度(92±0.2)和中度生活质量受损(55±0.3)。
- 与单纯标准治疗相比,CTCA在6个月时身体受限改善更小(差值-1.74(95%CI -3.34至-0.14),p=0.0329)。
- 与单纯标准治疗相比,CTCA在6个月时心绞痛频率改善更小(差值-1.55(-2.85至-0.25),p=0.0198)。
- 与单纯标准治疗相比,CTCA在6个月时生活质量改善更小(差值-3.48(-4.95至-2.01),p<0.0001)。
- 接受CTCA者中,诊断为正常冠状动脉或停用预防治疗者症状改善最大,中度非阻塞性病变或新处方预防治疗者改善最小(所有p<0.001)。
关键数值与推荐
- 身体受限差值-1.74(95%CI -3.34至-0.14),p=0.0329,CTCA组较标准治疗组改善更小。
- 心绞痛频率差值-1.55(95%CI -2.85至-0.25),p=0.0198,CTCA组较标准治疗组改善更小。
- 生活质量差值-3.48(95%CI -4.95至-2.01),p<0.0001,CTCA组较标准治疗组改善更小。
- 接受CTCA者中,正常冠状动脉或停用预防治疗者症状改善最大,中度非阻塞性病变或新处方预防治疗者改善最小,所有p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events. The effect on patient symptoms is currently unknown. METHODS: In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA. Symptoms and quality of life were assessed over 6 months using the Seattle Angina Questionnaire and Short Form 12. RESULTS: Baseline scores indicated mild physical limitation (74±0.4), moderate angina stability (44±0.4), modest angina frequency (68±0.4), excellent treatment satisfaction (92±0.2) and moderate impairment of quality of life (55±0.3). Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference -1.74 (95% CIs, -3.34 to -0.14), p=0.0329), angina frequency (difference -1.55 (-2.85 to -0.25), p=0.0198) and quality of life (difference -3.48 (-4.95 to -2.01), p<0.0001) at 6 months. For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all). CONCLUSIONS: While improving diagnosis, treatment and outcome, CTCA is associated with a small attenuation of the improvements in symptoms and quality of life due to the detection of moderate non-obstructive coronary artery disease. TRIAL REGISTRATION NUMBER: NCT01149590.
引用
- Williams MC, Hunter A, Shah A, et al. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart. 2017. PMID: 28246175. doi:10.1136/heartjnl-2016-310129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。